Developed by Eli Lilly, it has demonstrated substantial weight-loss outcomes in Phase 2 trials
Additionally, lawyers are not taking Ozempic cases for those being treated for cancer
However, because Gier et al 25 claimed that PanIN may express GLP1R in a large percentage of cases, we examined a large number of PanIN cases
This matters enormously for consumers and for litigation
Greg Dillon, founder and president of Lower Fifth Psychiatric in New York City and an assistant professor of psychiatry and public health at the Weill Cornell Medical College and New York Presbyterian Hospital Cornell, explained that it is essential for us to think of what there is to gain and lose from taking GLP-1 drugs
The impact of the drugs extends beyond healthcare, potentially boosting economic productivity and labour force participation as obesity rates decline